Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


After Pfizer And GSK, India’s Agila Teams Up With Lilly For Oncology Drugs In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

Over the last year, Agila has gone ballistic with its filings and approvals for anti-cancer injectables in the U.S., and after inking a deal with Lilly, it is likely to reach a new high.

You may also be interested in...

Pfizer, Strides Arcolab Join Forces To Manufacture And Market Oncology Injectables In U.S.

MUMBAI - After partnering with Aurobindo Pharma and Claris to source more than 100 oral and injectable generic drugs last year, Pfizer continues its shopping spree in India as it sealed yet another sourcing deal, this time with Bangalore-based Strides Arcolab

GSK Inks “Transformational” Licensing Agreement With Onco Therapies To Extend Reach In Emerging Markets

MUMBAI - British drug maker GlaxoSmithKline has announced a comprehensive product licensing deal, in what it calls a "transformational agreement" with Onco Therapies - a joint venture between South Africa's largest drug firm Aspen Pharmacare and one of India's largest generic drug exporters Strides Arcolab

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts